Системный обзор эпидемиологии и терапии болезни Пейрони

М. Г. Романюк

Аннотация


В работе представлены обзорные данные и результаты различных исследований относительно эпидемиологии, анамнеза и терапии болезни Пейрони (БП). БП является распространенным заболеванием, однако этиология этого заболевания остается до конца не изученной. Существует множество вариантов лечения, но далеко не все являются результативными. Был проведен обзор эпидемиологического состояния проблемы, а также нехирургических и хирургических методик лечения БП. Появление новых и весьма эффективных видов лечения может помочь улучшить информированность пациентов, и, соответственно, снизить распространенность болезни.

Ключевые слова


болезнь Пейрони; эректильная дисфункция; обзор

Полный текст:

PDF

Литература


Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol. 1997;157:276–281.

Devine CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol. 1997;157(1):285–290. [Available from: http://www.ncbi.nlm.nih.gov/pubmed/8976281. Accessed March 8, 2015].

Taylor FL, Levine LA. Peyronie’s disease. Urol Clin North Am. 2007;34:517–534.

Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88:727–730.

Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991;146(4):1007–1009. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1895413. Accessed March 9, 2015.

Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:10–13.

Shiraishi K, Shimabukuro T, Matsuyama H. The prevalence of Peyronie’s disease in Japan: a study in men undergoing maintenance hemodialysis and routine health checks. J Sex Med. 2012;9:2716–2723.

La Pera G, Pescatori ES, Calabrese M, et al; SIMONA Study Group. Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50–69 years. Eur Urol. 2001;40(5):525–530. [Available from: http://www.ncbi.nlm.nih.gov/pubmed/11752860. Accessed March 10, 2015].

Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171(6 pt 1): 2350–2353. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15126819. Accessed March 7, 2015.

Gholami SS, Gonzalez-Cadavid NF, Lin C-S, Rajfer J, Lue TF. Peyronie’s disease: a review. J Urol. 2003;169(April):1234–1241.

Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie’s disease: a case-control study. BJU Int. 2006;97:570–574.

Kendirci M, Trost L, Sikka SC, Hellstrom WJG. Diabetes mellitus is associated with severe Peyronie’s disease. BJU Int. 2007;99:383–386.

Rhoden EL, Riedner CE, Fuchs SC, Fuchs S, Ribeiro EP, Halmenschlager G. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie’s disease. J Sex Med. 2010;7(4 pt 1):1529–1537.

Nugteren HM, Nijman JM, de Jong IJ, van Driel MF. The association between Peyronie’s and Dupuytren’s disease. Int J Impot Res. 2011;23(4):142–145.

Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case-control study on risk factors for Peyronie’s disease. J Clin Epidemiol. 1998;51(6):511–515. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9636000. Accessed June 2, 2015.

Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med. 2008;5(8):1985–1990.

Smith JF, Walsh TJ, Conti SL, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie’s disease. J Sex Med. 2008;5(9):2179–2184.

Hellstrom WJG, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190(2):627–634.

Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175:2115–2118. discussion 2118.

Chung E, De Young L, Brock GB. Penile duplex ultrasonography in men with Peyronie’s disease: is it veno-occlusive dysfunction or poor cavernosal arterial inflow that contributes to erectile dysfunction? J Sex Med. 2011;8(12):3446–3451.

El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol. 1997;158(4):1391–1394.

Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3(2):111–115. quiz 116.

Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int. 2010;106:240–248.

Smith JF, Shindel AW, Huang Y-C, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl. 2011;13(2):322–325.

Nehra A, Alterowitz R, Culkin DJ, et al; American Urological Association Education and Research, Inc. Peyronie’s disease: AUA guideline. J Urol. 2015;194(3):745–753.

Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178(4):1398–1403.

Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: a randomized and prospective study. Urology. 2006;67(5):1038–1042. doi:10.1016/j.urology.2005.11.005.

Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91(6):522–524.

Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTA-BATM) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530–535.

Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie’s disease? A pilot study. Urology. 1994;44(2):291–295. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8048212. Accessed June 16, 2015.

Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16(3):238–243.

Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol. 1999;162(6):2003–2005. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10569556. Accessed June 16, 2015.

Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int. 2001;88:63–67.

Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie’s disease. Eur Urol. 2007;51(3):640–647.

Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010;22(5):298–309.

Lacy GL, Adams DM, Hellstrom WJG. Intralesional interferon-alpha-2b for the treatment of Peyronie’s disease. Int J Impot Res. 2002;14(5):336–339.

Hellstrom WJG, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176(1):394–398.

Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJG. Outcomes of intralesional interferon-a2B for the treatment of Peyronie disease. J Urol. 2013;190(6):2194–2199.

Favilla V, Russo GI, Privitera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie’s disease: a prospective, randomised controlled study. Andrologia. 2013;46(8):936–942.

Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA. 1996;93(11):5478–5482. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=39271&tool=pmcentrez&rendertype=abstract. Accessed June 16, 2015.

Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004. doi:10.1097/01.ju.0000127744.18878.f1.

Pendleton C, Wang R. Peyronie’s disease: current therapy. Transl Androl Urol. 2013;2(3):15–23.

Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620–626.

Gelbard M, Goldstein I, Hellstrom WJG, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207.

Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248–258.

Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468–1473.

Yafi F A, Pinsky MR, Stewart C, et al. The Effect of Duration of Penile Traction Therapy in Patients Undergoing Intralesional Injection Therapy for Peyronie’s Disease. J Urol. 2015;(6):1–5.

Raheem AA, Garaffa G, Raheem TA, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106(8):1178–1180.

Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol. 2007;177(3):972–975.

Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie’s disease: exploratory meta-analysis of clinical trials. J Urol. 2004;171(2 pt 1): 740–745.

Palmieri A, Imbimbo C, Longo N, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol. 2009;56(2):363–370.

Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie’s disease: EVIDENCE-based 2010 guidelines. J Sex Med. 2010;7(7):2359–2374.

Levine LA, Larsen SM. Surgery for Peyronie’s disease. Asian J Androl. 2012;15(1):27–34.

Ohebshalom M, Mulhall J, Guhring P, Parker M. Measurement of penile curvature in Peyronie’s disease patients: comparison of three methods. J Sex Med. 2007;4(1):199–203.

Andrews HO, Al-Akraa M, Pryor JP, Ralph DJ. The Nesbit operation for congenital curvature of the penis. Int J Impot Res. 1999;11(3):119–122. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10404279. Accessed June 16, 2015.

Yachia D. Modified corporoplasty for the treatment of penile curvature. J Urol. 1990;143(1):80–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2294269. Accessed June 16, 2015.

Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol. 2002;167(5):2066–2069.

Brant WO, Bella AJ, Lue TF. 16-Dot procedure for penile curvature. J Sex Med. 2007;4(2):277–280.

Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol. 2006;175(1):238–241.

Taylor FL, Levine LA. Surgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long(term follow up. J Sex Med. 2008;5(9):2221–2228.

Tornehl CK, Carson CC. Surgical alternatives for treating Peyronie’s disease. BJU Int. 2004;94(6):774–783.

Taylor FL, Abern MR, Levine LA. Predicting erectile dysfunction following surgical correction of Peyronie’s disease without inflatable penile prosthesis placement: vascular assessment and preoperative risk factors. J Sex Med. 2012;9(1):296–301.

Cormio L, Zucchi A, Lorusso F, et al. Surgical treatment of Peyronie’s disease by plaque incision and grafting with buccal mucosa. Eur Urol. 2009;55(6):1469–1476.

Gelbard MK. Relaxing incisions in the correction of penile deformity due to Peyronie’s disease. J Urol. 1995;154(4):1457–1460. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7658558. Accessed June 16, 2015.

Kadioglu A, Sanli O, Akman T, Ersay A, Guven S, Mammadov F. Graft materials in Peyronie’s disease surgery: a comprehensive review. J Sex Med. 2007;4(3):581–595.

Teloken C, Grazziotin T, Rhoden E, et al. Penile straightening with crural graft of the corpus cavernosum. J Urol. 2000;164(1):107–108.

Knoll LD. Use of small intestinal submucosa graft for the surgical management of Peyronie’s disease. J Urol. 2007;178(6):2474–2478. discussion 2478.

Chun JL, McGregor A, Krishnan R, Carson CC. A comparison of dermal and cadaveric pericardial grafts in the modified Horton-Devine procedure for Peyronie’s disease. J Urol. 2001;166(1):185–188.

John T, Bandi G, Santucci R. Porcine small intestinal submucosa is not an ideal graft material for Peyronie’s disease surgery. J Urol. 2006;176(3):1025–1029.

Hatzichristodoulou G, Gschwend JE, Lahme S. Surgical therapy of Peyronie’s disease by partial plaque excision and grafting with collagen fleece: feasibility study of a new technique. Int J Impot Res. 2013;25(5):183-187.

Usta MF, Bivalacqua TJ, Sanabria J, Koksal IT, Moparty K, Hellstrom WJG. Patient and partner satisfaction and long-term results after surgical treatment for Peyronie’s disease. Urology. 2003;62(1):105–109.

Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie’s disease. J Sex Med. 2007;4(5):1500–1508.

Leungwattanakij S, Bivalacqua TJ, Reddy S, Hellstrom WJ. Long-term follow-up on use of pericardial graft in the surgical management of Peyronie’s disease. Int J Impot Res. 2001;13(3):183–186. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11525318. Accessed June 16, 2015.

Levine LA, Estrada CR. Human cadaveric pericardial graft for the surgical correction of Peyronie’s disease. J Urol. 2003;170(6 pt 1): 2359–2362.

Breyer BN, Brant WO, Garcia MM, Bella AJ, Lue TF. Complications of porcine small intestine submucosa graft for Peyronie’s disease. J Urol. 2007;177(2):589–591.

Staerman F, Pierrevelcin J, Ripert T, Menard J. Medium-term follow-up of plaque incision and porcine small intestinal submucosal grafting for Peyronie’s disease. Int J Impot Res. 2010;22(6):343–348.

Lee EW, Shindel AW, Brandes SB. Small intestinal submucosa for patch grafting after plaque incision in the treatment of Peyronie’s disease. Int Braz J Urol. 2008;34(2):191–196. discussion 197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18462517. Accessed June 16, 2015.

Perito P, Wilson S. The Peyronie’s plaque «scratch»: an adjunct to modeling. J Sex Med. 2013;10(5):1194–1197. [Available from: http://www.ncbi.nlm.nih.gov/pubmed/23750353. Accessed December 21, 2015].

Rolle L, Ceruti C, Timpano M, et al. A new, innovative, lengthening surgical procedure for Peyronie’s disease by penile prosthesis implantation with double dorsal-ventral patch graft: the «sliding technique». J Sex Med. 2012;9(9):2389–2395.

Sansalone S, Garaffa G, Djinovic R, et al. Simultaneous penile lengthening and penile prosthesis implantation in patients with Peyronie’s disease, refractory erectile dysfunction, and severe penile shortening. J Sex Med. 2012;9(1):316–321.




DOI: https://doi.org/10.30841/зм.v0i3 (58).104076

Copyright (c) 2016 Здоровье мужчины

Creative Commons License
Эта работа лицензирована Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-5547 (Online), ISSN 2307-5090 (Print)